The definition of the target population is listed below, and in addition we need access to patients with at least one blood eosinophil count to be able to stratify these patients by blood eosinophil levels: 1.- GINA steps 4 and 5 2.- Optimal treatment (continuous treatment with high dose inhaled corticosteroids and long-acting ?2 agonists with or without additional maintenance asthma controllers when not experiencing an asthma exacerbation) 3.- Uncontrolled asthma (? 2 asthma exacerbations in the previous year) Please advice on the feasibility to use eg SIDIAP in connection to hospitalization data to identify at least 400 patients with this definition, and also how common it is to do blood tests for eosinophils in Spain. Però al tractar-se d?un exploratori, per poder donar una contesta ràpida, em valorat de mirar, en principi, només aquests criteris: Dx Asma: J45 + Determinació Eosinofilia en analítica

Background and objectives: Prurigo nodularis (PN) is a chronic highly pruritic skin condition characterised by the presence of hyperkeratotic, excoriated, pruritic papules and nodules. No published epidemiology on the rate of PN in Europe or the US was found in searches of the literature or through discussions with key opinion leaders. The objective is to estimate incidence and ?life-time? prevalence rates for PN in Catalonia, Spain (2009 ? 2013). Methods: The study design is a retrospective, descriptive, observational study with all variables identified from SIDIAP database of primary care records. The study population will be those people permanently registered with a general practice for at least one day between 1st January 2009 and 31st December 2013. Records will be searched for a specific ICD 10 code (L28.1 prurigo nodularis). Sex and age at onset will be obtained from SIDIAP. Analysis: Patient-years at risk will be estimated for the study population in total, by year and by age – sex group (10 year groups). The incidence of PN will be calculated in total and in each sub-group. The ?life-time prevalence? will be estimated from the number of people who are active on 31st December 2013 and the number with a code for PN dated at any time before this.

Agomelatine (Valdoxan, Thymanax) is a melatonergic agonist and 5-HT2C antagonist indicated for major depressive episodes in adults. In February 2009, marketing authorisation was granted in the European Union for the treatment of adults with major depression, and agomelatine is now on the market in 41 countries. Agomelatine has been proven to be superior to placebo and similar to existing antidepressants (venlafaxine, fluoxetine, and sertraline) in short-term clinical trials and three longer-term relapse-prevention trials. Patients with depression treated with agomelatine describe improved sleep quality. As agomelatine does not raise serotonin levels, it has less potential for the common gastrointestinal, sexual, or metabolic side- effects than other antidepressant compounds. However, hepatotoxic reaction is an identified risk included in the risk management plan (RMP). Indeed, based on the last summary of product characteristics (SmPC) dated October 2012, 1.4% of patients treated with 25 mg of agomelatine and 2.5% of patients treated with 50 mg showed elevated transaminases (Les Laboratoires Servier, 2012). In addition, as a risk minimisation measure, the SmPC recommends that transaminase levels be checked at treatment initiation and then after 3, 6, 12, and 24 weeks and also following a dose increase.